Genmab A/S February 2025 SEC Report: Key Insights & Annual Meeting Announcement
Here are the key insights extracted from the provided section of the financial report:
- Filing Type: The document is a Form 6-K, which is used by foreign private issuers to report significant events to the U.S. Securities and Exchange Commission (SEC).
- Company Information:
- Name: Genmab A/S
- Commission File Number: 001-38976
- Address: Carl Jacobsens Vej 30, 2500 Valby, Denmark
- Contact: +45 70 20 27 28
- Reporting Period: The report is for the month of February 2025.
- Incorporation by Reference: This report will be incorporated by reference in Genmab A/S’s registration statements filed on Form S-8. The associated file numbers are:
- 333-232693
- 333-253519
- 333-262970
- 333-277273
- 333-284876
- Signature:
- Signed by Anthony Pagano, who holds the title of Executive Vice President & Chief Financial Officer.
- Date of Signature: February 13, 2025.
- Exhibit Index:
- An exhibit is referenced as 99.1, which includes a company announcement dated February 13, 2025, about the notice to convene the Annual General Meeting of Genmab A/S.
This information is significant as it outlines the company's compliance with SEC reporting requirements, provides key contact and business information, and highlights upcoming corporate governance actions (the Annual General Meeting).